NIH-Funding

By: YJ

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 17:46

Thanks, Mine was 6th percentile. Per my recent discussion with the PO, current payline is 7the percentile for R21.

Categories: NIH-Funding

By: R21_Hopeful

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 17:37

Congratulations @YJ. Were you at 7th percentile or better for an R21?

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 17:11

Congratulations – you should get some of that cut back (maybe all, depending on whether it was all due to CR) once the budget passes.

Categories: NIH-Funding

By: YJ

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 17:00

FYI, I recently received an NOA of my NCI R21 application with 13% budget cut. Mine was 6%.

Categories: NIH-Funding

By: KK

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 16:44

Thanx for the answer. I sure hope the budget does get passed soon and with an increase so we could at least have the same payline as last year.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 16:41

The entire NIH is operating at 90% of their FY17 appropriation, but since no IC knows the outcome of the federal budget (ie, whether they will receive the appropriation they anticipate), they are very conservative in making awards just in case something unexpected occurs and they receive a cut rather than a slight increase in funding levels. At NCI, then, awards being made during the CR would be well below the 10th percentile and probably selected based on programmatic priority as well. During this period of federal budget uncertainty, rather than ask your PO if you will be funded, you could ask if you should prepare a resubmission (or new submission).

Categories: NIH-Funding

By: KK

WriteEdit-Grant Questions Blog - Wed, 12/20/2017 - 15:34

Is there any information on the 2018 NCI payline yet? What is the payline that is currently being awarded while we are still on a CR? Thanx

Categories: NIH-Funding

Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 13:46
Funding Opportunity PA-18-531 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.
Categories: NIH-Funding

Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 13:46
Funding Opportunity PA-18-532 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.
Categories: NIH-Funding

Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 13:46
Funding Opportunity PA-18-529 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA)is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.
Categories: NIH-Funding

Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01)

NIH Funding Announcements - Wed, 12/20/2017 - 11:37
Funding Opportunity PAR-18-534 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.
Categories: NIH-Funding

Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 11:23
Funding Opportunity PAR-18-514 from the NIH Guide for Grants and Contracts. This funding opportunity (FOA) encourages small business-based (STTR) research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.
Categories: NIH-Funding

Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 11:22
Funding Opportunity PAR-18-512 from the NIH Guide for Grants and Contracts. This funding opportunity (FOA) encourages small business-based (SBIR) research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.
Categories: NIH-Funding

Sensory and motor system changes as predictors of preclinical Alzheimers disease (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 10:57
Funding Opportunity PAR-18-519 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimers disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.
Categories: NIH-Funding

NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required)

NIH Funding Announcements - Wed, 12/20/2017 - 10:40
Funding Opportunity PAR-18-523 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project
Categories: NIH-Funding

NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)

NIH Funding Announcements - Wed, 12/20/2017 - 10:39
Funding Opportunity PAR-18-522 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial.
Categories: NIH-Funding

NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)

NIH Funding Announcements - Wed, 12/20/2017 - 10:38
Funding Opportunity PAR-18-521 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair's Grant application. Specifically, this FOA encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.
Categories: NIH-Funding

CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/20/2017 - 03:30
Funding Opportunity PAR-18-543 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Categories: NIH-Funding

NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional)

NIH Funding Announcements - Wed, 12/20/2017 - 03:29
Funding Opportunity PAR-18-542 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Categories: NIH-Funding

Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 12/20/2017 - 02:29
Funding Opportunity RFA-TR-18-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for the Tissue Chip Testing Center (TCTC) Microphysiological Systems (MPS) Data Center (MPS DC), which supports the NIH Tissue Chip Consortium. The Consortium facilitates the development, validation and dissemination of tissue chip (TC) technology through support for collaborative research in 1) development of tissue chips for toxicity and safety testing of promising therapeutics (RFA-RM-11-022); 2) development of tissue chips for disease modeling and efficacy testing (RFA-TR-16-017 and RFA-TR-16-019); and 3) independent validation of tissue chip platforms through the TCTCs (RFA-TR-16-006). The MPS DC is expected to be the central clearinghouse for TC data management, and will incorporate novel approaches and technologies for data management, data mining and meta-analyses, and data sharing across many organs and tissues, diseases, data types, and TC platforms. The MPS Data center is expected to provide different levels of public and tiered access to TC information for basic and clinical researchers, academic and practicing physicians, the pharmaceutical industry, NIH, FDA and other government agencies, patients, and the lay public. The MPS Data Center will work with IQ Consortium members to develop and make available a secure, customizable coordinated data management system for collection, storage, and analyses of diverse data types from multiple TC platforms being developed and used for drug screening, safety and efficacy testing.
Categories: NIH-Funding